These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 29497575)
1. Pimavanserin: A Novel Drug Approved to Treat Parkinson's Disease Psychosis. Kitten AK; Hallowell SA; Saklad SR; Evoy KE Innov Clin Neurosci; 2018 Feb; 15(1-2):16-22. PubMed ID: 29497575 [No Abstract] [Full Text] [Related]
2. Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis. Meltzer HY; Mills R; Revell S; Williams H; Johnson A; Bahr D; Friedman JH Neuropsychopharmacology; 2010 Mar; 35(4):881-92. PubMed ID: 19907417 [TBL] [Abstract][Full Text] [Related]
3. Pimavanserin: A Novel Antipsychotic for Parkinson's Disease Psychosis. Bozymski KM; Lowe DK; Pasternak KM; Gatesman TL; Crouse EL Ann Pharmacother; 2017 Jun; 51(6):479-487. PubMed ID: 28375643 [TBL] [Abstract][Full Text] [Related]
4. Blinded SAPS-PD Assessment After 10 Weeks of Pimavanserin Treatment for Parkinson's Disease Psychosis. Isaacson SH; Coate B; Norton J; Stankovic S J Parkinsons Dis; 2020; 10(4):1389-1396. PubMed ID: 32716320 [TBL] [Abstract][Full Text] [Related]
5. On the discovery and development of pimavanserin: a novel drug candidate for Parkinson's psychosis. Hacksell U; Burstein ES; McFarland K; Mills RG; Williams H Neurochem Res; 2014 Oct; 39(10):2008-17. PubMed ID: 24682754 [TBL] [Abstract][Full Text] [Related]
7. Pimavanserin in the Treatment of Parkinson's Disease Psychosis: Meta-analysis and Meta-regression of Randomized Clinical Trials. Mansuri Z; Reddy A; Vadukapuram R; Trivedi C; Amara A Innov Clin Neurosci; 2022; 19(1-3):46-51. PubMed ID: 35382074 [TBL] [Abstract][Full Text] [Related]
8. Serotonin 2A Receptor Inverse Agonist as a Treatment for Parkinson's Disease Psychosis: A Systematic Review and Meta-analysis of Serotonin 2A Receptor Negative Modulators. Yasue I; Matsunaga S; Kishi T; Fujita K; Iwata N J Alzheimers Dis; 2016; 50(3):733-40. PubMed ID: 26757194 [TBL] [Abstract][Full Text] [Related]
9. Pimavanserin in Parkinson's Disease-induced Psychosis: A Literature Review. Patel RS; Bhela J; Tahir M; Pisati SR; Hossain S Cureus; 2019 Jul; 11(7):e5257. PubMed ID: 31572642 [TBL] [Abstract][Full Text] [Related]
10. The effects of treatment with pimavanserin on activities of daily living in patients with Parkinson's disease psychosis: a 16-week, single-arm, open-label study. Evidente VGH; DeKarske D; Coate B; Abler V Ther Adv Neurol Disord; 2024; 17():17562864241228350. PubMed ID: 38476466 [TBL] [Abstract][Full Text] [Related]
11. Perspective on Pimavanserin and the SAPS-PD: Novel Scale Development as a Means to FDA Approval. Schubmehl S; Sussman J Am J Geriatr Psychiatry; 2018 Oct; 26(10):1007-1011. PubMed ID: 30072306 [TBL] [Abstract][Full Text] [Related]
12. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. Cummings J; Isaacson S; Mills R; Williams H; Chi-Burris K; Corbett A; Dhall R; Ballard C Lancet; 2014 Feb; 383(9916):533-40. PubMed ID: 24183563 [TBL] [Abstract][Full Text] [Related]
14. Evidence for using pimavanserin for the treatment of Parkinson's disease psychosis. Tampi RR; Tampi DJ; Young JJ; Balachandran S; Hoq RA; Manikkara G World J Psychiatry; 2019 Jun; 9(3):47-54. PubMed ID: 31211112 [TBL] [Abstract][Full Text] [Related]
15. Pimavanserin, a novel antipsychotic for management of Parkinson's disease psychosis. Kianirad Y; Simuni T Expert Rev Clin Pharmacol; 2017 Nov; 10(11):1161-1168. PubMed ID: 28817967 [TBL] [Abstract][Full Text] [Related]
16. Nighttime Sleep and Daytime Sleepiness Improved With Pimavanserin During Treatment of Parkinson's Disease Psychosis. Patel N; LeWitt P; Neikrug AB; Kesslak P; Coate B; Ancoli-Israel S Clin Neuropharmacol; 2018; 41(6):210-215. PubMed ID: 30303817 [TBL] [Abstract][Full Text] [Related]
18. Pimavanserin use in a movement disorders clinic: a single-center experience. Mahajan A; Bulica B; Ahmad A; Kaminski P; LeWitt P; Taylor D; Krstevska S; Patel N Neurol Sci; 2018 Oct; 39(10):1767-1771. PubMed ID: 30032332 [TBL] [Abstract][Full Text] [Related]
19. Pimavanserin for the treatment of Parkinson's disease psychosis. Chendo I; Ferreira JJ Expert Opin Pharmacother; 2016 Oct; 17(15):2115-24. PubMed ID: 27609312 [TBL] [Abstract][Full Text] [Related]
20. Pimavanserin for psychosis in Parkinson's disease dementia: Subgroup analysis of the HARMONY Trial. Weintraub D; Espay AJ; Sharma VD; Tariot PN; Abler V; Pathak S; Stankovic S Parkinsonism Relat Disord; 2024 Feb; 119():105951. PubMed ID: 38113700 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]